Table 2.

Differences between serum ceramides (C) (nmol/ml) and sphingosine-1-phosphate (S1P) (pmol/ml) concentrations in psoriatic patients with different body weight. Data are shown as median and quartiles (Q1, Q3), (*min.–max. value)

Sphingolipid	Psoriasis BMI < 25 n = 28	Psoriasis 25 ≤ BMI < 30 n = 30	Psoriasis BMI < 30 n = 58	Psoriasis BMI ≥ 30 n = 27	BMI < 30 vs. BMI ≥ 30
C. myristic (C14:0)	1.6 (1.2–2.0)	1.3 (1.1–3.7)	1.5 (1.1–2.1)	1.1 (0.9–3.8)	NS
C. palmitic (C16:0)	8.4 (7.2–10.1)	8.0 (6–9.5)	8.3 (6.8–9.7)	7.5 (6.0–8.8)	NS
C. palmitoleic (C16:1)	0.7 (0.6–1.1)	0.6 (0.6–1.1)	0.7 (0.6–1.1)	0.7 (0.5–1.0)	NS
C. stearic (C18:0)	7.0 (5.7–8.3)	6.5 (5.3–7.8)	6.9 (5.6–8.0)	6.1 (5.5–7.3)	NS
C. oleic (C 18:1)	1.9 (1.8–2.2)	1.8 (1.7–2.1)	1.8 (1.7–2.2)	1.8 (1.7–2.0)	NS
C. linoleic (C18:2)	0.1 (0.0–0.4)	0.1 (0.0–0.3)	0.1 (0.0–0.4)	0.0 (0–0.3)	NS
C. arachidic (C20:0)	0.4 (0.4–0.5)	0.4 (0.4–0.4)	0.4 (0.4–0.5)	0.4 (0.4–0.5)	NS
C. linolenic (C18:3)	0.2 (0.2–0.2)	0.2 (0.1–0.2)	0.2 (0.2–0.2)	0.2 (0.2–0.2)	NS
C. behenic (C22:0)	1.2 (1.1–1.3)	1.2 (1.1–1.4)	1.2 (1.1–1.3)	1.3 (1.1–1.6)	p= 0.030
C. arachidonic (C20:4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	0.3 (0.3–0.4)	NS
C. lignoceric (C24:0)	2.9 (2.5–3.2)	3.0 (2.3–3.6)	2.9 (2.5–3.3)	3.1 (2.7–3.6)	NS
C. eicosapentaenoic (C20:5)	0.0 (0.0–2.9)*	0.0 (0.0–0.6)*	0.0 (0.0–2.9)*	0.0 (0.0–1.0)*	NS
C. nervonic (C24:1)	2.0 (1.8–2.2)	2.1 (1.9–2.3)	2.1 (1.9–2.2)	2.0 (1.9–2.4)	NS
C docosahexaenoic (C 22:6)	0.5 (0.0–0.6)	0.4 (0.0–0.5)	0.5 (0.0–0.6)	0.2 (0.0–0.5)	NS
C. total	29.4 (24.8–32.5)	27.6 (21.8–33.6)	28.8 (23.7–32.9)	26.4 (23.2–32.2)	NS
S1P	541.1 (477.2–574.3)	506.5 (457.8–559.8)	522.0 (457.8–570.9)	467.4 (419.8–530.9)	p= 0.026